AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04246684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid, 400 mg/m2
Description: 2h-civ day 22, 36, 50, 64, 78, 92, 106, 120, and 134 of therapyfor Control arm; 400 mg/m2, 2h-civ d 64, d78, d92, d106, d120, d134 of therapy for experimental arm
Study NCT00552240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine 200 mg QD
Description: 200 mg QD
Study NCT00552240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine 200 mg BID
Description: 200 mg BID
Study NCT00552240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir 300 mg
Description: 300 mg QD
Study NCT00552240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir 100 mg
Description: 100 mg QD
Study NCT00580645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: 2mg/day or 1mg/day with 1-week medication lead-in period.
Study NCT00580645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02679573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delafloxacin
Description: Antibacterial agent, 300 mg IV, Q12H for at least 6 doses with potential to switch to 450 mg oral tablet, Q12H for up to 20 doses total
Study NCT04246684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid, 400 mg/m2
Description: 2h-civ day 22, 36, 50, 64, 78, 92, 106, 120, and 134 of therapyfor Control arm; 400 mg/m2, 2h-civ d 64, d78, d92, d106, d120, d134 of therapy for experimental arm
Study NCT04246684 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy control, 5x5 Gy: 25 Gy
Description: Control arm: 5x5 Gy (total: 25 Gy) 5 fractions
Study NCT04246684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine, 1000 mg/m2
Description: 1000 mg/m2 (twice daily) day1-14 every three weeks instead of 5FU optional
Study NCT04246684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, 1000 mg/m2
Description: 1000 mg/m2 (twice daily) day1-14 every three weeks instead of 5FU optional
Study NCT04246684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 85 mg/m2
Description: 85 mg/m2, 2h-civ, d64, d78, d92, d106, d120, d134 of therapy
Study NCT04246684 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy experimental, 30 x 1,8 Gy: 54 Gy
Description: 30 x 1.8 Gy (total: 54 Gy), 5 fractions per week
Study NCT04246684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, 825 mg/m2
Description: 825 mg/m2 bid, per os, on day 1-14, 22-35 of RT instead of 5FU optional
Study NCT04246684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin, 130 mg/m2
Description: day1every three weeks (optional)
Study NCT02679573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Antibacterial Agent, 400 mg IV, Q24H for at least 3 doses with potential to switch to 400 mg oral over-encapsulated tablet, Q24H for up to 10 doses total
Study NCT02679573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Antibacterial Agent, at local investigator discretion, subjects in the moxifloxacin arm with confirmed MRSA can switch to linezolid 600 mg IV Q12H for all remaining doses
Study NCT01096485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Emergency Pill (BAY86-5028/Opxion)
Description: Single dose of 1.5 mg coated tablet
Study NCT01096485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel (Postday)
Description: Single dose of two 0.75 mg tablets
Study NCT01351831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation with strength training
Description: The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of balance-, mobility- and functional training exercises etc. In addition, the participants perform unilateral (operated leg) knee-extensions and leg presses in 2 sets for each strength training exercise, using relative loads of 12 RM (week 1), 10 RM (weeks 2-5), and 8 RM (week 6-7). All sets are performed to failure.
Study NCT01351831 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation without strength training
Description: The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of the same balance-, mobility- and functional training exercises etc. as used in the other experimental arm.
Study NCT02545023 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete an in-person one-on-one interview
Study NCT02545023 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete the demographics questionnaire, SCNS-34, SF-36, and Lifestyle Needs Survey
Study NCT00149760 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Augmented Standard Medical Care
Description: Participants' physicians will receive a letter making specific treatment recommendations for primary care treatment.
Study NCT00149760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Affective Behavior Therapy
Description: Individually-administered cognitive-behavioral therapy with an emotional focus in addition to augmented standard medical care
Study NCT01947985 — intervention group
Intervention type: DRUG
Intervention: Rivaroxoban (Xarelto, Bay59-7939)
Description: The treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors (20 mg rivaroxaban \[od\], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\]).
Study NCT01947985 — intervention group
Intervention type: DRUG
Intervention: Standard of care
Description: For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
Study NCT00297596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered as an 8 mg/kg loading dose by intravenous (IV) infusion over 90 minutes on day 1 of cycle 1. Subsequent doses will be administered as a 6 mg/kg IV dose over 30 minutes.
Study NCT00297596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered at a dose of 130 mg/ m2 over 120 minutes on day 1 of each cycle, following standard antiemetic premedications. 21 day cycles.~For the first cycle, trastuzumab will be administered before oxaliplatin; however for subsequent cycles, oxaliplatin will be infused prior to trastuzumab
Study NCT04304521 — intervention group
Intervention type: PROCEDURE
Intervention: Lung recruitment maneuver
Description: Lung recruitment maneuver is used to reopen or prevent collapsed lung under mechanical ventilation so as to decrease respiratory complications. LRM induces a transient increase in intra-thoracic pressure and decreases in venous return, leading to a decrease in left ventricular end-diastolic area and stroke volume.
Study NCT02717572 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F 18
Study NCT02717572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Study NCT02717572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized Tomography
Study NCT02717572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Study NCT00669526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BCBT
Description: Brief Cognitive Behavioral Therapy. This BCBT protocol consists of up to 8 CBT sessions to be conducted over a maximum of 12 weeks.
Study NCT00669526 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMHC referral
Description: Referral to local Speciality Mental Health Care. Families were referred to local mental health care providers, and could freely choose any treatment or combination of treatments offered (e.g., anti-depressant medication, individual psychotherapy, family psychotherapy, etc.).
Study NCT01667211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel plus nedaplatin
Description: intravenous albumin-bound paclitaxel, 175-200 mg/m2, d 1, was given every 3 weeks, combined with intravenous nedaplatin, 80- 100 mg/m2, d 2. At least 2 cycles will be completed for each patient, for whom responds to study treatment, 4-6 cycles will be completed.
Study NCT04395027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: atrial septal defect closure
Description: The iatrogenic septal defect will be closed in the usual manner
Study NCT02764294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Group
Description: Music group was listened to a music of their choise with a headset. The music intervention was started about 10-15 minutes before cystoscopy and continued during the whole procedure. Types of music were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
Study NCT02764294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stress Ball Group
Description: Music group was given stress ball into both their palms about 10-15 minutes before cystoscopy. Participants were instructed to squeeze the balls twice after counting up to five and repeat it until the end of the procedure.
Study NCT02764294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DVD Group
Description: DVD group was started to be watched a DVD of their choise about 10-15 minutes before cystoscopy and continued during the whole procedure.
Study NCT03465098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strict low carbohydrate diet (< 3gr/day of carbohydrate) before a 18F-FDG PET/CT
Description: The patients will receive 2 PET/CT , first exam with standard diet preceded by 12h fasting and second exam preceded by 3 meals strict low diet and 12h fasting
Study NCT01853137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed Lingual Mandibular Growth Modificator (FLMGM)
Description: Novel Class II functional appliance, a fixed version of double-plate appliance
Study NCT02483585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered once a month by subcutaneous injection
Study NCT02483585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once a month by subcutaneous injection
Study NCT03634020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DynamX Sirolimus-eluting Coronary Bioadaptor System
Description: de novo native coronary artery lesions
Study NCT01485055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab and Basiliximab
Description: Participants in this research study will receive combination therapy (2 drugs: Infliximab and Basiliximab)once a week for four weeks. Both drugs will be given through the participant's broviac, port or through a vein in the arm. It will take about 4-5 hours to complete the 2-drug combination therapy each week. Participants will be given pre-medications to help prevent reactions to the study drugs.~Infliximab will be given at a dose of 10mg per Kg per dose. Basiliximab will be given in 10mg doses to patients who weigh less than 35kg. Patients who weigh weigh more than 35kg will receive 20mg doses. Patients will receive both drugs weekly on days 1,8,15 and 22. Each drug will be given 4 times.
Study NCT03987178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dunk
Description: If randomized to Dunk, the subject is asked to submerge his or her head in the hot tub at least up to brow level.
Study NCT03987178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to Hot Tub
Description: Subjects will be asked to sit in a hot tub for 15 minutes (with an individual timer).
Study NCT03987178 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exposure to Hot Tub
Description: Subjects will be asked to sit in a hot tub for 15 minutes (with an individual timer).
Study NCT02042222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Study NCT03830749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag Oral Tablet 25-75 mg daily for 12 weeks plus pulsed dexamethasone
Study NCT01411215 — intervention group
Intervention type: DRUG
Intervention: Enbrel
Description: 25mg biweekly or 50mg per week, subcutaneous injection
Study NCT00394082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: 125 mg/m\^2 of ABI-007 administered by intravenously (IV) over 30 minutes on days 1, 8 and 15 of each 28 day cycle.
Study NCT00394082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab administered once every 2 weeks (10 mg/kg) by IV infusion after ABI-007 has been given. The first dose is one Day 1, cycle 1.
Study NCT00903630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: administered by mouth at the assigned dose daily for each 28 day cycle
Study NCT00903630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: administered at a fixed dose of 40 mg/m\^2 intravenously (IV) on day 1 of each 28 day cycle
Study NCT01553123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate
Description: once daily, oral
Study NCT01553123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iron
Description: once daily, dried ferrous sulfate
Study NCT01553123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron
Description: once daily, dried ferrous sulfate
Study NCT03080831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 0.9% in Glucose 5% + 40mmol/L Potassium
Description: Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
Study NCT03080831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucion 5%
Description: Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
Study NCT04525872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full parenteral nutrition light protection of the bag, tubing and lipids
Description: Each infant enrolled in this study will receive full PN light protection including the PN bag, lipids and tubing.
Study NCT02645188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cueing
Description: Verbal and tactile cueing to enhance gluteus maximus recruitment
Study NCT04025580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flucelvax
Description: Seasonal influenza vaccine
Study NCT04025580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluvirin
Description: Seasonal influenza vaccine
Study NCT04025580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High Dose
Description: Seasonal influenza vaccine for adults ages 65 and older
Study NCT06352164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Description: The investigators selected acupoints including Zhongwan (CV12) and bilateral Shangjuxu (ST37), Sanyinjiao (SP6), Gongsun (SP4), Taichong (LR3), Taixi (KI3), Hegu (LI4), and Quchi (LI11)17 according to the World Health Organization standard. Single-use 0.30×40 mm or 0.30×25 mm acupuncture needles (Hwato, Suzhou, China) were vertically inserted into each acupoint to 20-30 mm depth to obtain a deqi sensation (a soreness, distention, numbness or heaviness sensation). Bilateral Zusanli (ST36) and Tianshu (ST25) were selected for moxibustion. Pure moxa sticks (diameter: 2.8 cm; Hanyi, Nanyang, China) were ignited and fixed on a moxibustion stand at a distance of 3-5 cm to the surface of acupoints. The temperature of skin surface at the acupoints was maintained at 43 ± 1°C and monitored with a miniature infrared thermometer (Fluke 62, Fluke Corporation, Everett, WA, USA). Acupuncture and moxibustion were concomitantly performed for 30 min.
Study NCT03377309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fycompa
Description: Dose will be increased by 2mg/day increments every one week to reach a maximum dose of 8 mg/day. Treatment phase will be stable dose for 12 weeks then followed by washout period over 2 weeks.
Study NCT01801735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam Test Capsules
Study NCT02344004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAI (Liposomal Amikacin for Inhalation) 590 mg
Description: LAI 590 mg QD, administered by inhaling drug product that had been aerosolized in an eFlow nebulizer over approximately 14 minutes.
Study NCT02995954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril/Amlodipine
Description: Single table containing Perindopril/Amlodipine
Study NCT01768117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086
Description: 0.5 ml intramuscular injection of 120 microgram bivalent rLP2085 administered at 0, 2 and 6 months
Study NCT04618328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all trans retinoic acid
Description: ATRA is given concomitantly at a daily dose of 10 mg twice daily orally for 12 weeks
Study NCT02165254 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PLUS
Description: 1 hour tai chi session 3 times a week (weeks 1-12), to twice a week (week 13-16), and every other week (week 17-26) for a total of 24 weeks
Study NCT02165254 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LITE
Description: 1 hour tai chi session 3 times a week (weeks 1-12)
Study NCT04463017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HU6
Description: HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
Study NCT04463017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HU6
Description: HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
Study NCT05638997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument assisted manipulation + Core exercises
Description: The effect of Instrument assisted manipulation on chronic non-spesific low back pain
Study NCT05638997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan mobilization with movement + Core exercises
Description: The effect of Mulligan mobilization with movement on chronic non-spesific low back pain
Study NCT05638997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core exercises
Description: The effect of core exercises on chronic non-spesific low back pain
Study NCT02939170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A Multifocal Contact Lenses with Molded Mark
Study NCT02939170 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delefilcon A Multifocal Contact Lenses
Study NCT00722930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y90 Ibritumomab Tiuxetan
Description: Consolidation with Y90 Ibritumomab Tiuxetan
Study NCT01798121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: To compare new PPD to reference standard material
Description: Aplisol@ will be compared to reference standard material
Study NCT01798121 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: To compare new PPD to reference standard material
Description: Aplisol@ will be compared to reference standard material
Study NCT01798121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reference standard
Description: Response of reference standard material compared to Aplisol@.
Study NCT04509115 — intervention group
Intervention type: DRUG
Intervention: Short-acting opioid prescription for acute pain
Description: Patients not currently using opioids who receive a new short-acting opioid prescription as part of routine care for acute pain will be recruited and followed prospectively for 180 days.
Study NCT02084056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Linagliptin
Study NCT02084056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin
Study NCT02084056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin FDC
Description: Linagliptin/Metformin FDC
Study NCT01952054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: 120 mg subcutaneously on Day 1 of every 28 day cycle.